What is Enlivex Ltd.'s earnings per share (EPS)?

Enlivex Ltd. (ENLV) reported diluted earnings per share of $25.48 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Enlivex Ltd. (ENLV) Financials

ENLV

FY2025 annual

Net Income $1.2B +8329.2% YoY

EPS (Diluted) $25.48 YoY not available

Free Cash Flow -$10.5M +20.0% YoY

Operating Cash Flow -$10.4M +19.9% YoY

Market Cap $5.1M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings 0.0x on $1.2B net income, FY2025

Price / Book 0.0x on $1.9B equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 25, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENLV SEC filings page.

This page shows Enlivex Ltd. (ENLV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

Enlivex Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Enlivex Ltd. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$0.01used

For every $1 of reported earnings, Enlivex Ltd. used $0.01 of operating cash (-$10.4M OCF vs $1.2B net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$1.9M

YoY-42.6%

QoQ+0.1%

Enlivex Ltd. held $1.9M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

237M

Enlivex Ltd. had 237M shares outstanding in Q4 2025.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

ENLV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENLV quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
R&D Expenses	$9.2M-13.4%	$10.6M-44.1%	$19.0M+1.7%	$18.7M+45.1%	$12.9M+111.6%	$6.1M+8.6%	$5.6M+39.6%	$4.0M+137.3%	$1.7M-81.0%	$8.9M+15.4%	$7.7M+73.2%	$4.4M+506.7%	$732K+422.9%	$140K
SG&A Expenses	$5.8M+18.0%	$4.9M-20.0%	$6.1M-13.6%	$7.1M+10.9%	$6.4M+73.2%	$3.7M+22.7%	$3.0M+134.4%	$1.3M+167.9%	$480K-91.9%	$5.9M-15.1%	$7.0M+163.5%	$2.6M+534.4%	$416K+383.7%	$86K
Operating Income	-$15.0M+5.4%	-$15.9M+45.9%	-$29.4M-13.9%	-$25.8M-33.7%	-$19.3M-97.1%	-$9.8M-13.5%	-$8.6M-62.7%	-$5.3M-144.1%	-$2.2M+86.3%	-$15.9M-2.5%	-$15.5M-118.6%	-$7.1M-516.7%	-$1.1M-408.0%	-$226K
EBITDA	-$14.7M+4.2%	-$15.3M+46.3%	-$28.6M-21.0%	-$23.6M-25.9%	-$18.7M-97.3%	-$9.5M-12.9%	-$8.4M-62.5%	-$5.2M-148.0%	-$2.1M+86.8%	-$15.8M-2.4%	-$15.5M-118.5%	-$7.1M-516.3%	-$1.1M-408.0%	-$226K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$2K	$0
Income Tax	$382.6M	N/A	N/A	N/A	N/A	N/A	N/A	-$4K-114.3%	$28K-87.0%	$216K+800.0%	$24K	$0	$0	N/A
Net Income	$1.2B+8329.2%	-$15.0M+48.3%	-$29.1M+6.4%	-$31.1M-114.7%	-$14.5M-22.4%	-$11.8M-26.0%	-$9.4M-121.2%	-$4.2M-69.4%	-$2.5M+84.4%	-$16.0M-4.3%	-$15.4M-118.8%	-$7.0M-513.3%	-$1.1M-400.0%	-$229K
EPS (Basic)	$27.04+3804.1%	-$0.73+53.2%	-$1.56+7.7%	-$1.69-108.6%	-$0.81+10.0%	-$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$25.48	-$0.73+53.2%	-$1.56+7.7%	-$1.69-108.6%	-$0.81+10.0%	-$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	48M	21M+10.4%	19M+1.0%	18M+3.0%	18M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
R&D Expenses	N/A	$2.1M+7.1%	N/A	N/A	$2.0M-60.3%	N/A	N/A	$5.0M+22.5%
SG&A Expenses	N/A	$937K-5.1%	N/A	N/A	$987K-38.8%	N/A	N/A	$1.6M-8.3%
Operating Income	N/A	-$3.1M-3.1%	N/A	N/A	-$3.0M+55.1%	N/A	N/A	-$6.6M-13.3%
EBITDA	N/A	-$3.0M-5.9%	N/A	N/A	-$2.8M	N/A	N/A	N/A
Net Income	N/A	-$1.9M+39.7%	-$3.5M+16.6%	N/A	-$3.1M+54.4%	-$4.1M+42.6%	N/A	-$6.8M+31.5%
EPS (Basic)	N/A	-$0.08+50.0%	N/A	N/A	-$0.16+56.8%	N/A	N/A	-$0.37+31.5%
EPS (Diluted)	N/A	-$0.08+50.0%	N/A	N/A	-$0.16+56.8%	N/A	N/A	-$0.37+31.5%
Diluted Shares (Avg)	N/A	24M+22.1%	N/A	N/A	20M	N/A	N/A	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

ENLV Balance Sheet

ENLV quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$2.3B+8304.7%	$27.7M-24.8%	$36.8M-45.6%	$67.6M-28.9%	$95.1M+135.8%	$40.4M+129.8%	$17.6M+59.1%	$11.0M+204.6%	$3.6M-65.9%	$10.6M-48.2%	$20.5M-37.7%	$33.0M+10669.3%	$306K	N/A
Current Assets	$1.7B+6606.3%	$26.0M-23.0%	$33.8M-35.5%	$52.3M-39.5%	$86.4M+126.8%	$38.1M+132.1%	$16.4M+59.8%	$10.3M+183.7%	$3.6M-65.6%	$10.5M-48.3%	$20.4M-38.0%	$32.9M+10898.3%	$299K	N/A
Cash & Equivalents	$1.9M-42.6%	$3.3M+306.0%	$813K-98.4%	$49.9M+345.9%	$11.2M+97.5%	$5.7M+43.7%	$3.9M-59.4%	$9.7M	N/A	$3.0M-58.2%	$7.3M-31.2%	$10.6M+3819.6%	$270K+84.9%	$146K
Short-Term Investments	$3.9M+1850.0%	$198K-96.1%	$5.1M+1608.4%	$299K-99.5%	$62.9M	$0	$0	$0	N/A	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0
Total Liabilities	$392.1M+9466.9%	$4.1M-39.3%	$6.7M-37.5%	$10.8M+6.9%	$10.1M+107.5%	$4.9M-22.4%	$6.3M+372.7%	$1.3M+127.3%	-$4.9M-162.3%	$7.8M+202.6%	$2.6M+13.3%	$2.3M+1640.5%	$131K	N/A
Current Liabilities	$9.0M+137.5%	$3.8M-37.3%	$6.1M-8.3%	$6.6M+40.0%	$4.7M+7.9%	$4.4M-26.9%	$6.0M+429.2%	$1.1M+145.7%	$460K-76.2%	$1.9M-23.2%	$2.5M+10.3%	$2.3M+1640.5%	$131K	N/A
Non-Current Liabilities	$383.0M+128003.3%	$299K-56.4%	$686K-83.6%	$4.2M-22.2%	$5.4M+980.0%	$499K+67.4%	$298K+50.5%	$198K-43.6%	$351K-94.0%	$5.9M+8312.9%	$70K	$0	$0	N/A
Total Equity	$1.9B+8102.8%	$23.6M-21.6%	$30.1M-47.1%	$56.8M-33.2%	$85.0M+139.6%	$35.5M+214.5%	$11.3M+16.2%	$9.7M+14.3%	$8.5M+202.2%	$2.8M-84.3%	$17.9M-41.5%	$30.7M+17428.0%	$175K+133.3%	$75K
Retained Earnings	$1.1B+972.0%	-$127.1M-13.4%	-$112.1M-35.0%	-$83.0M-59.8%	-$52.0M-38.6%	-$37.5M-46.1%	-$25.7M-57.6%	-$16.3M+64.4%	-$45.8M-14.9%	-$39.8M-67.4%	-$23.8M-182.4%	-$8.4M-501.6%	-$1.4M	N/A

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Total Assets	$2.3B+8304.7%	$22.6M-29.2%	N/A	$27.7M-24.8%	$31.9M-39.8%	N/A	$36.8M-45.6%	$53.0M-31.4%
Current Assets	$1.7B+6606.3%	$21.3M-25.4%	N/A	$26.0M-23.0%	$28.6M-7.2%	N/A	$33.8M-35.5%	$30.8M-52.7%
Cash & Equivalents	$1.9M-42.6%	$1.9M-49.5%	N/A	$3.3M+306.0%	$3.7M+8.4%	N/A	$813K-98.4%	$3.5M-82.8%
Short-Term Investments	$3.9M+1850.0%	$6K-97.4%	N/A	$198K-96.1%	$228K-99.1%	N/A	$5.1M+1608.4%	$25.4M
Long-Term Investments	$0	$0	N/A	$0	$0	N/A	$0	$0
Total Liabilities	$392.1M+9466.9%	$3.5M+6.1%	N/A	$4.1M-39.3%	$3.3M-61.6%	N/A	$6.7M-37.5%	$8.7M-1.8%
Current Liabilities	$9.0M+137.5%	$3.3M+17.1%	N/A	$3.8M-37.3%	$2.8M-43.1%	N/A	$6.1M-8.3%	$5.0M+18.5%
Non-Current Liabilities	$383.0M+128003.3%	$216K-56.7%	N/A	$299K-56.4%	$499K-86.5%	N/A	$686K-83.6%	$3.7M-20.2%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$7.2M
Total Equity	$1.9B+8102.8%	$19.1M-33.3%	$20.6M-23.2%	$23.6M-21.6%	$28.6M-35.6%	$26.9M-46.9%	$30.1M-47.1%	$44.3M-35.3%
Retained Earnings	$1.1B+972.0%	-$132.4M-11.0%	N/A	-$127.1M-13.4%	-$119.3M-23.0%	N/A	-$112.1M-35.0%	-$97.0M-38.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

ENLV Cash Flow Statement

ENLV quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$10.4M+19.9%	-$13.0M+44.7%	-$23.5M+1.8%	-$24.0M-36.5%	-$17.5M-59.4%	-$11.0M-56.3%	-$7.0M-122.7%	-$3.2M-37.2%	-$2.3M+85.1%	-$15.5M-16.9%	-$13.2M-200.5%	-$4.4M-409.7%	-$865K-480.5%	-$149K
Depreciation & Amortization	$332K-39.1%	$545K-34.7%	$835K-62.0%	$2.2M+302.4%	$546K+90.9%	$286K+38.8%	$206K+70.2%	$121K+45.8%	$83K+118.4%	$38K+123.5%	$17K+240.0%	$5K	$0	$0
Stock-Based Compensation	$1.8M-13.7%	$2.1M+5.8%	$2.0M-28.1%	$2.7M-6.9%	$2.9M+334.9%	$670K-17.3%	$810K-19.7%	$1.0M+733.9%	$121K-82.7%	$700K-73.3%	$2.6M+256.4%	$736K+189.8%	$254K+2722.2%	$9K
Capital Expenditures	$68K-34.0%	$103K-56.4%	$236K-97.1%	$8.1M+399.8%	$1.6M+59.5%	$1.0M+428.0%	$193K-58.1%	$461K+254.6%	$130K+622.2%	$18K-62.5%	$48K-23.8%	$63K+3050.0%	$2K	$0
Free Cash Flow	-$10.5M+20.0%	-$13.1M+44.8%	-$23.8M+25.9%	-$32.1M-67.3%	-$19.2M-59.4%	-$12.0M-66.2%	-$7.2M-99.7%	-$3.6M-48.8%	-$2.4M+84.3%	-$15.5M-16.6%	-$13.3M-197.3%	-$4.5M-415.8%	-$867K-481.9%	-$149K
Investing Cash Flow	-$1.3M-114.6%	$9.1M+134.9%	-$26.0M-141.5%	$62.5M+262.8%	-$38.4M-83.1%	-$21.0M-229.9%	-$6.4M-1169.3%	-$501K-285.4%	-$130K-101.4%	$9.0M-9.7%	$10.0M	N/A	N/A	N/A
Financing Cash Flow	$10.4M+60.8%	$6.5M+1692.8%	$360K+140.0%	$150K-99.8%	$61.0M+84.3%	$33.1M+298.3%	$8.3M+59.9%	$5.2M-35.5%	$8.1M+32.3%	$6.1M	$0	N/A	N/A	N/A

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Depreciation & Amortization	N/A	$85K-46.9%	N/A	N/A	$160K	N/A	N/A	N/A
Stock-Based Compensation	N/A	$295K-24.0%	N/A	N/A	$388K-24.1%	N/A	N/A	$511K-26.7%

Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

ENLV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENLV quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Return on Equity	63.8%+127.5pp	-63.6%+33.0pp	-96.6%-42.0pp	-54.6%-37.6pp	-17.0%+16.3pp	-33.3%+49.9pp	-83.2%-39.5pp	-43.7%-14.2pp	-29.5%+540.7pp	-570.2%-484.5pp	-85.7%-62.8pp	-22.9%+631.4pp	-654.3%-349.0pp	-305.3%
Return on Assets	53.1%+107.3pp	-54.2%+24.7pp	-78.9%-33.0pp	-45.9%-30.7pp	-15.2%+14.1pp	-29.3%+24.1pp	-53.4%-15.0pp	-38.4%+30.7pp	-69.1%+81.6pp	-150.7%-75.8pp	-74.9%-53.6pp	-21.3%+352.9pp	-374.2%	N/A
Current Ratio	193.24+186.4x	6.84+1.3x	5.57-2.3x	7.92-10.4x	18.32+9.6x	8.72+6.0x	2.75-6.3x	9.09+1.2x	7.87+2.4x	5.46-2.7x	8.11-6.3x	14.42+12.1x	2.28	N/A
Debt-to-Equity	0.200.0x	0.17-0.1x	0.220.0x	0.19+0.1x	0.120.0x	0.14-0.4x	0.56+0.4x	0.14	N/A	2.78+2.6x	0.14+0.1x	0.07-0.7x	0.75	N/A

Metric	Q4'2520-F	Q2'256-K	Q1'256-K	Q4'2420-F	Q2'246-K	Q1'246-K	Q4'2310-K	Q2'2310-Q
Return on Equity	N/A	-9.8%+1.0pp	-16.7%-1.3pp	N/A	-10.8%+4.5pp	-15.4%-1.2pp	N/A	-15.3%-0.9pp
Return on Assets	N/A	-8.3%+1.4pp	N/A	N/A	-9.7%+3.1pp	N/A	N/A	-12.8%0.0pp
Current Ratio	193.24+186.4x	6.41-3.6x	N/A	6.84+1.3x	10.06+3.9x	N/A	5.57-2.3x	6.17-9.3x
Debt-to-Equity	0.200.0x	0.19+0.1x	N/A	0.17-0.1x	0.120.0x	N/A	0.220.0x	0.160.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Enlivex Ltd. ENLV	FY2025	N/A	$1.2B	N/A	$5.1M	—
Akari Therapeutics plc AKTX	FY2025	N/A	-$17.3M	N/A	$20.0M	—
SeaStar Medical Holding Corporation ICU	FY2025	$1.2M	-$12.2M	N/A	$19.0M	44/100
Tenax Therapeutics, Inc. TENX	FY2025	$0	-$52.6M	N/A	$70.0M	—
Rein Therapeutics, Inc. RNTX	FY2025	$0	-$49.9M	N/A	$68.5M	—
Q32 Bio Inc. QTTB	FY2025	$53.7M	$29.8M	55.5%	$248.3M	67/100

Where Enlivex Ltd. Ranks

Frequently Asked Questions

Is Enlivex Ltd. profitable?

Yes, Enlivex Ltd. (ENLV) reported a net income of $1.2B in fiscal year 2025.

What is Enlivex Ltd.'s EBITDA?

Enlivex Ltd. (ENLV) had EBITDA of -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Enlivex Ltd.'s return on equity (ROE)?

Enlivex Ltd. (ENLV) has a return on equity of 63.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Enlivex Ltd.'s free cash flow?

Enlivex Ltd. (ENLV) recorded an outflow of $10.5M in free cash flow during fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Enlivex Ltd.'s operating cash flow?

Enlivex Ltd. (ENLV) recorded an outflow of $10.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Enlivex Ltd.'s total assets?

Enlivex Ltd. (ENLV) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Enlivex Ltd.'s capital expenditures?

Enlivex Ltd. (ENLV) invested $68K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Enlivex Ltd. spend on research and development?

Enlivex Ltd. (ENLV) invested $9.2M in research and development during fiscal year 2025.

How many shares does Enlivex Ltd. have outstanding?

Enlivex Ltd. (ENLV) had 237M shares outstanding as of fiscal year 2025.

What is Enlivex Ltd.'s current ratio?

Enlivex Ltd. (ENLV) had a current ratio of 193.24 as of fiscal year 2025, which is generally considered healthy.

What is Enlivex Ltd.'s debt-to-equity ratio?

Enlivex Ltd. (ENLV) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enlivex Ltd.'s return on assets (ROA)?

Enlivex Ltd. (ENLV) had a return on assets of 53.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Enlivex Ltd.'s P/E ratio?

Enlivex Ltd. (ENLV) trades at 0.0x earnings, its market capitalization divided by net income of $1.2B net income, FY2025. The market capitalization is $5.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Enlivex Ltd.'s price-to-sales ratio?

Enlivex Ltd. (ENLV) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $5.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Enlivex Ltd.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Enlivex Ltd. (ENLV) held $5.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.4M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Enlivex Ltd.'s Piotroski F-Score?

Enlivex Ltd. (ENLV) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enlivex Ltd.'s earnings high quality?

For every $1 of reported earnings, Enlivex Ltd. (ENLV) used $0.01 of operating cash (-$10.4M OCF vs $1.2B net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.